Routine Heparin for Patients with Cancer? One Answer, More Questions

被引：36
作者：
Akl, Elie A. [1 ,2 ]
Schuenemann, Holger J. [2 ,3 ]
机构：
[1] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 07期
关键词：
D O I：
10.1056/NEJMe1113672
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：661 / 662
页数：2
相关论文
共 4 条
  • [1] Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
    Agnelli, Giancarlo
    George, Daniel J.
    Kakkar, Ajay K.
    Fisher, William
    Lassen, Michael R.
    Mismetti, Patrick
    Mouret, Patrick
    Chaudhari, Umesh
    Lawson, Francesca
    Turpie, Alexander G. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) : 601 - 609
  • [2] [Anonymous], COCHRANE DATABASE SY
  • [3] Heparin as an Inhibitor of Cancer Progression
    Borsig, Lubor
    [J]. GLYCOSAMINOGLYCANS IN DEVELOPMENT, HEALTH AND DISEASE, 2010, 93 : 335 - 349
  • [4] Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer
    van Doormaal, Frederiek F.
    Di Nisio, Marcello
    Otten, Hans-Martin
    Richel, Dick J.
    Prins, Martin
    Buller, Harry R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2071 - 2076
1